Cadrenal Therapeutics Partners with Abbott for Tecarfarin Pivotal Study in HeartMate 3™ LVAD Patients
Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a biopharmaceutical company specializing in cardiovascular therapeutics, has announced the signing of a Collaboration Agreement with Abbott (NYSE: ABT). This partnership will support Cadrenal’s pivotal trial, the TECarfarin Anticoagulation and Hemocompatibility with Left Ventricular Assist Devices (TECH-LVAD) study, which focuses on their late-stage oral Vitamin K antagonist (VKA) asset, tecarfarin.
Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a biopharmaceutical company focused on developing specialized therapeutics for rare cardiovascular conditions, has entered into a significant collaboration with Abbott (NYSE: ABT). Under the terms of the Collaboration and Data Sharing Agreement, Abbott will support Cadrenal’s pivotal TECarfarin Anticoagulation and Hemocompatibility with Left Ventricular Assist Devices (TECH-LVAD) trial. This trial will evaluate the efficacy and safety of tecarfarin, a novel oral Vitamin K antagonist (VKA), in patients with Left Ventricular Assist Devices (LVADs).
As part of the collaboration, Abbott will provide valuable insights from recent HeartMate 3™ trials and support Cadrenal with trial design, site identification, trial awareness, and expertise related to the HeartMate 3™ LVAD. Abbott’s participation strengthens Cadrenal’s access to key clinical trial sites and enhances the efforts for patient enrollment in the trial.
“We are thrilled to have the support of Abbott, a global healthcare leader, as we move into late-stage clinical development of tecarfarin,” said Quang X. Pham, Chief Executive Officer of Cadrenal Therapeutics. “This partnership further validates our commitment to advancing tecarfarin as a potential new option for patients with implanted cardiac devices. Together, we have a unique opportunity to evaluate tecarfarin in combination with Abbott’s HeartMate 3™ LVAD, and this brings us one step closer to providing the first innovation in Vitamin K-targeted anticoagulation in over 70 years.”
The HeartMate 3™ LVAD is a state-of-the-art mechanical circulatory support device designed to help patients with advanced heart failure. It is the most advanced LVAD currently available in the U.S. and has been recognized for its strong clinical track record. Abbott’s heart pumps have set the standard in LVAD therapy, and the HeartMate 3™ LVAD is now the most advanced LVAD in the market. According to Business Research Insights, the LVAD market was valued at $1.1 billion in 2023 and is expected to grow to $2.4 billion by 2032.
Cadrenal Therapeutics is developing tecarfarin to address the unmet needs of individuals with implanted cardiac devices. Warfarin, the widely used oral anticoagulant, has several well-documented drawbacks, including a high risk of side effects, complex dosing regimens, and a requirement for frequent monitoring.
Although warfarin is used off-label for cardiovascular conditions involving LVADs, extensive clinical and real-world data have shown that it is not the ideal option for these patients. Tecarfarin, in contrast, has been designed to offer a safer and more effective alternative, addressing many of the challenges associated with warfarin use. By doing so, Cadrenal aims to improve outcomes for patients who rely on implanted cardiac devices while minimizing the need for frequent monitoring and reducing the risk of complications associated with traditional anticoagulants.
The collaboration with Abbott represents a key step forward in Cadrenal’s mission to develop better treatment options for rare cardiovascular conditions. Tecarfarin has already received Orphan Drug designation (ODD) for advanced heart failure patients with LVADs, and the company has also received ODD and fast-track status for tecarfarin in the treatment of end-stage kidney disease and atrial fibrillation (ESKD+AFib). These designations are a testament to the significant unmet medical need in these patient populations and the potential of tecarfarin to offer a new, more effective treatment option.
Cadrenal’s product-in-a-pipeline approach, with tecarfarin at its core, is focused on delivering innovative solutions for patients with rare cardiovascular conditions. By advancing tecarfarin through clinical trials and regulatory processes, Cadrenal aims to address the longstanding challenges associated with anticoagulation therapy in patients with implanted cardiac devices. The collaboration with Abbott will help accelerate the development of this promising new treatment, providing both organizations with the resources and expertise needed to bring tecarfarin to the market.
As Cadrenal moves forward with the TECH-LVAD trial, the company remains focused on its goal of providing safer, more effective treatments for patients with advanced cardiovascular conditions. The partnership with Abbott, a trusted leader in medical technology, is a crucial step in achieving this goal and underscores the potential for tecarfarin to become a breakthrough therapeutic for patients with LVADs.
About Cadrenal Therapeutics, Inc.
Cadrenal Therapeutics is a late-stage biopharmaceutical company dedicated to developing specialized therapeutics for rare cardiovascular conditions. The company’s late-stage asset, tecarfarin, is a new oral Vitamin K antagonist (VKA) that aims to be a safer and more effective anticoagulant than warfarin for individuals with implanted cardiac devices. Tecarfarin has already received Orphan Drug designation for patients with advanced heart failure and LVADs, as well as fast-track status for the treatment of end-stage kidney disease and atrial fibrillation. Through its innovative approach, Cadrenal Therapeutics is working to address the unmet medical needs of patients with rare cardiovascular diseases.
